Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524887 | 0.89 | HDAC1 (0.49) | HRH3HDAC1HDAC6 | |
| SCHEMBL3527863 | 0.83 | ADRA1D (0.41) | HRH3ADRA1AADRA1DADRA1BHDAC1 | |
| SCHEMBL3529731 | 0.82 | ROCK1 (0.45) | HRH3HDAC1HDAC6 | |
| SCHEMBL3524800 | 0.82 | NOTUM (0.44) | HRH3HDAC1HDAC6 | |
| SCHEMBL8203733 | 0.79 | TAAR1 (0.59) | HRH3ADRA1AADRA1DADRA1BHDAC1 | |
| SCHEMBL3524521 | 0.77 | NOTUM (0.40) | HRH3 | |
| SCHEMBL3533600 | 0.76 | RORC (0.44) | HRH3ADRA1AADRA1DADRA1BHDAC1 | |
| SCHEMBL4828614 | 0.74 | TAAR1 (0.56) | HDAC1HDAC6 | |
| SCHEMBL3529275 | 0.72 | NOTUM (0.39) | ADRA1AADRA1DADRA1B | |
| SCHEMBL12404781 | 0.68 | BRD4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | claimed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7858652-B2 | Substituted 4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2084152-A2 | SUBSTITUTED 4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| WO-2008058867-A2 | SUBSTITUTED 4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139533-A1 | SUBSTITUTED 4-IMIDAZOLES | TAAR1, TAAR5, TACR1 | HRH3 62/4885ADRA1A 41/4885ADRA1D 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.